Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy

Area of Science:

• Oncology and Pharmacology
• Molecular Biology and Biochemistry

Background:

• Targeted cancer therapies, including tyrosine kinase inhibitors and monoclonal antibodies, have significantly improved survival in metastatic cancers.
• Reactive oxygen species (ROS) are well-established mediators of cytotoxicity in traditional chemotherapy and radiotherapy.
• The role of oxidative stress regulation in targeted cancer therapies is an emerging field.

Purpose of the Study:

• To comprehensively review the current evidence on ROS-mediated effects of tyrosine kinase inhibitors and monoclonal antibodies.
• To explore the relevance of ROS in the context of drug resistance in targeted cancer therapies.
• To identify potential strategies for overcoming drug resistance through modulation of ROS.

Main Methods:

• Systematic literature review of preclinical and clinical studies.
• Analysis of data on ROS generation and oxidative stress markers associated with targeted cancer agents.
• Evaluation of studies investigating the link between ROS and drug resistance mechanisms.

Main Results:

• Substantial evidence indicates that certain tyrosine kinase inhibitors and monoclonal antibodies induce ROS-mediated effects.
• These ROS-mediated effects are implicated in both the therapeutic efficacy and potential adverse events of these targeted agents.
• Emerging data suggest a critical role for ROS in the development of drug resistance.

Conclusions:

• Targeted cancer therapies exhibit significant ROS-mediated effects that are crucial for their mechanism of action.
• Understanding and modulating ROS pathways presents a promising strategy for enhancing the effectiveness of targeted cancer treatments.
• Targeting ROS may offer novel approaches to overcome drug resistance in solid malignancies and lymphomas.